Trials / Completed
CompletedNCT05997524
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer: A Multicenter, Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Trastuzumab plus chemotherapy prolonged the median overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Among chemotherapy regimens, oxaliplatin is generally more convenient and tolerable than cisplatin, and becoming an increasingly popular option for the treatment of AGC. The aim of the study was to evaluate the efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin (CAPOX) in HER2-positive AGC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w). |
| DRUG | Oxaliplatin | Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for up to 6 cycles. |
| DRUG | Capecitabine | Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval. |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2022-02-28
- Completion
- 2023-06-30
- First posted
- 2023-08-18
- Last updated
- 2023-08-18
Locations
1 site across 1 country: Bangladesh
Source: ClinicalTrials.gov record NCT05997524. Inclusion in this directory is not an endorsement.